Capital at risk

Investment strategy

Health Innovation

Healthcare is undergoing monumental change. Perhaps more than any other sector, it offers extreme payoffs for those seeking long-term disruptive investments. Companies developing technologies that improve outcomes for large numbers of patients can grow exponentially. Our quest is to own those rare firms for long periods while they transform the full value chain of human health.  

Abstract depiction of DNA against a dark blue background.

Radical change, radical possibilities

The future of human health is radically changing. We aim to find and invest in companies addressing society’s biggest problems to make healthcare more efficient and accessible, in turn generating strong long-term returns for our clients.  

Health Innovation Strategy

Investment manager, Julia Angeles, discusses the Baillie Gifford Health Innovation Strategy.

Driving transformation

Our objective is to deliver +3 per cent (gross fees) against the MSCI ACWI on a rolling five-year basis by investing in the companies which are driving the transformation of healthcare, from diagnosis and treatment to efficiency and access.  

Our approach is agnostic to sector and benchmark composition. We aim to find and own those few companies that really matter in the theme and hold them in a concentrated portfolio of 25-50 names over the long term, generally for five years or more.   

The performance target is aspirational and is not guaranteed. We don’t use it to compile the portfolio and returns will vary. A single performance target may not be appropriate across all vehicles and jurisdictions. We may not meet our investment objectives if, for example, our growth investment style is out of favour, or we misjudge the long-term earnings growth of our holdings.

Different than the average

This is not just another healthcare sector fund. We are not restricted to the MSCI World Health Care Index – our opportunity set is much broader than that. This is a thematic fund. We are experiencing a great convergence of science and technology, and we are seeking the transformative companies at the heart of this. 

That's why we think we can offer something different. This approach isn't new to Baillie Gifford; we have been investing in innovation since our inception in 1908, and today close to 15 per cent of our clients’ assets are invested in leading healthcare companies.

Most of the exorbitant costs of healthcare today are associated with care that is not transformative and not personalised. It's clear that this model is unsustainable.
Marina Record

Meet the managers

Documents

Philosophy and process

Explore our investment process and idea generation as our Health Innovation investors believe it’s time to rethink what the term healthcare means.

Quarterly update

Get the latest investment commentary, portfolio overview, transactions and performance information alongside governance engagement and voting. 

Invest in this strategy

You can invest in this strategy through the following fund(s).

Explore further

Curious to learn more about our products and what we can offer you? Please get in touch.

Strategy portfolio holdings

A list of the top 10 holdings that the representative portfolio invests in.

All figures up to: 31 January 2024

#Holding% of portfolio
1Moderna6.9%
2Alnylam Pharmaceuticals6.5%
3Genmab6.0%
4ShockWave Medical5.9%
5argenx5.7%
6Dexcom5.4%
7Sartorius Group5.3%
8Ambu 4.9%
9Edwards Lifesciences4.3%
10Exact Sciences4.1%

Strategy holdings by country

All figures up to: 31 January 2024

1North America64.60%
2Europe (ex UK)28.50%
3Developed Asia Pacific2.80%
4Emerging Markets2.70%
5UK1.00%
6Cash0.40%
Total 100%

Strategy holdings by country

All figures up to: 31 January 2024

Total: 100%

Please note

The information contained on this page is intended as a guide only and should not be relied upon when making investment decisions. All holdings information is unaudited. Source Baillie Gifford & Co. Please note that totals may not add due to rounding.

Invest in this strategy

You can invest in this strategy through the following fund(s).

Explore further

Curious to learn more about our products and what we can offer you? Please get in touch.

How to invest in this strategy

You can invest in this strategy through the following fund(s).

Explore further

Curious to learn more about our products and what we can offer you? Please get in touch.

Important information

Please remember that all investment strategies have the potential for profit and loss and your or your clients’ capital may be at risk.
The information on this website is intended for institutional investors (as defined in the Securities and Futures Act, Chapter 289 of Singapore, as amended) and consultants in Singapore only. It is not intended for use by any other persons including members of the general public or investors from other jurisdictions.
The information contained in this website has been compiled with considerable care to ensure its accuracy at the date of publication. However, no representation or warranty, express or implied, is made to its accuracy or completeness. Nothing in this information or elsewhere in this website shall exclude, limit or restrict our duties and liabilities to you the United Kingdom's Financial Services and Markets Act 2000 or any conduct of business rules which we are bound to comply with. These Terms and any non-contractual obligations arising from or connected with them shall be governed by, and these Terms shall be construed in accordance with, the laws of Singapore.
Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK clients. Both are authorised and regulated by the Financial Conduct Authority.
Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 and a Type 2 licence from the Securities and Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes to professional investors in Hong Kong.
Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong, Telephone +852 3756 5700.
This website is informative only and the information provided should not be considered as investment or other advice or a recommendation or offer to buy, sell or hold a particular investment. You can read details of our Legal and Important Information here.
This website does not collect personal information. "Cookies" may be stored on your computer for easy navigation. A "cookie" does not allow us to identify you, but stores information about navigation through our website (such as pages already visited, time and date of visit) which we can remember during the user's next visit to our website in order to improve your browsing experience. If you have any enquiries in relation to our data protection policies and procedures, this Website or the information on it, please click here to contact Baillie Gifford.
This website is informative only and the information provided should not be considered as investment or other advice or a recommendation to buy, sell or hold a particular investment. You can read details of our Legal and Important Information here.